<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220737</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-VC-200-006</org_study_id>
    <nct_id>NCT03220737</nct_id>
  </id_info>
  <brief_title>VAXCHORA Pediatric Study to Assess Safety and Immunogenicity</brief_title>
  <official_title>A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to &lt;18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against&#xD;
      disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18&#xD;
      through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase&#xD;
      4 study are to evaluate the safety and immunogenicity of a single dose of VAXCHORA (1 x 10e9&#xD;
      cfu/dose) in children ages 2 years to &lt;18 years of age in developed countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, single-crossover study with three age&#xD;
      cohorts and two treatment groups within each cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">September 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a randomized, placebo-controlled, double-blind, single-crossover study with three age cohorts and two treatment groups within each cohort.&#xD;
The main study consists of a screening period of 30 days, a treatment period from Day 1 to Day 29, and a follow-up period through Day 181. Cohort 1 has an optional sub-study consisting of a long-term follow-up period through Day 730.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will be conducted as a double-blind study through 181, where neither the sponsor, the statistical team, study volunteer subjects, nor clinical site personnel (except for the unblinded administration staff) will know subjects' treatment assignment. Once each subject has reached their Day 181 visit they will be individually unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</measure>
    <time_frame>Day 11</time_frame>
    <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 (6 to &lt;12 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</measure>
    <time_frame>Day 11</time_frame>
    <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3 (2 to &lt;6 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</measure>
    <time_frame>Day 11</time_frame>
    <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1 (12-17 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</measure>
    <time_frame>Day 11</time_frame>
    <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 (6-11 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</measure>
    <time_frame>Day 11</time_frame>
    <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3 (2-5 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</measure>
    <time_frame>Day 11</time_frame>
    <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of18 and 45 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 91</measure>
    <time_frame>Day 91</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 91 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 181</measure>
    <time_frame>Day 181</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 181 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 365 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 547</measure>
    <time_frame>Day 547</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 547 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 730</measure>
    <time_frame>Day 730</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 730 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2 (6 to &lt;12 Years) - Seroconversion of SVA - Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3 (2 to &lt;6 Years) - Seroconversion of SVA - Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 1 for the subjects in the active treatment group and the placebo crossover group</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 91</measure>
    <time_frame>Day 91</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 91 for the subjects in the active treatment group and the placebo crossover group</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 181</measure>
    <time_frame>Day 181</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 181 for the subjects in the active treatment group and the placebo crossover group</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 365 for the subjects in the active treatment group who participate in the substudy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 547</measure>
    <time_frame>Day 547</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 547 for the subjects in the active treatment group who participate in the substudy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 730</measure>
    <time_frame>Day 730</time_frame>
    <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 730 for the subjects in the active treatment group who participate in the substudy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety - Solicited Adverse Events</measure>
    <time_frame>Through Day 8</time_frame>
    <description>Evaluate the safety and tolerability of VAXCHORA by collecting solicited adverse events (abdominal pain, headache, lack of appetite, tiredness, diarrhea, nausea, vomiting and fever) by age cohort and overall through Day 8</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety - Unsolicited Adverse Events</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Evaluate the safety and tolerability of VAXCHORA by collecting unsolicited adverse events by age cohort and overall through Day 29</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety - Serious Adverse Events</measure>
    <time_frame>Through Day 181</time_frame>
    <description>Evaluate the safety and tolerability of VAXCHORA by collecting serious adverse events by age cohort and overall through Day 181</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluate the acceptability of VAXCHORA using the percent of subjects in each age cohort able to complete the dosing according to protocol.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Cholera (Disorder)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (active, 12-17 yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 (placebo, 12 - 17 yrs)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (active, 6 - 11 yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (placebo, 6 - 11 yrs)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (active, 2 - 5 yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (placebo, 2 - 5 yrs)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Control: Adult Bridging Population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAXCHORA (Cholera Vaccine, Live, Oral)</intervention_name>
    <description>VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
    <arm_group_label>Cohort 1 (active, 12-17 yrs)</arm_group_label>
    <arm_group_label>Cohort 2 (active, 6 - 11 yrs)</arm_group_label>
    <arm_group_label>Cohort 3 (active, 2 - 5 yrs)</arm_group_label>
    <arm_group_label>Historical Control: Adult Bridging Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control for this study is normal (0.9%) saline.</description>
    <arm_group_label>Cohort 1 (placebo, 12 - 17 yrs)</arm_group_label>
    <arm_group_label>Cohort 2 (placebo, 6 - 11 yrs)</arm_group_label>
    <arm_group_label>Cohort 3 (placebo, 2 - 5 yrs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Between 2 and &lt;18 years of age on Day 1&#xD;
&#xD;
          -  In general good health&#xD;
&#xD;
          -  Able and willing to provide informed assent for study participation&#xD;
&#xD;
          -  Primary caregiver is able and willing to provide informed consent for study&#xD;
             participation&#xD;
&#xD;
          -  (for females of childbearing potential) Using an acceptable method of contraception&#xD;
             through Day 29&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current acute gastrointestinal illness or loose stools within 3 days of Day 1 visit&#xD;
&#xD;
          -  Current acute febrile illness&#xD;
&#xD;
          -  History of cholera infection&#xD;
&#xD;
          -  History of cholera vaccination&#xD;
&#xD;
          -  History of severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Pregnancy (for females of childbearing potential)&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, creates an unacceptable&#xD;
             risk to the subject&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, will interfere with the&#xD;
             conduct of the study or the validity of the data&#xD;
&#xD;
          -  Duration of &gt;2 weeks of abnormal stool pattern, defined as &lt;3 stools per week or &gt;2&#xD;
             stools per day in the past 6 months&#xD;
&#xD;
          -  Regular use of laxatives in the past 6 months&#xD;
&#xD;
          -  History of enterotoxigenic E. coli infection&#xD;
&#xD;
          -  Travel to cholera-endemic area in the previous 5 years&#xD;
&#xD;
          -  Nursing/Breastfeeding&#xD;
&#xD;
          -  Received or plans to receive the following from 14 days prior to the study vaccination&#xD;
             through 11 days after vaccination: Any other licensed vaccines, antibiotics, or&#xD;
             chloroquine&#xD;
&#xD;
          -  Received or plans to receive any other investigational agent throughout the main study&#xD;
             (Day 181)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Andre de Lame, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03220737/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03220737/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study included healthy volunteers (2 - 17 years) who were not previously immunized against cholera. A total of 574 subjects were screened, of which 24 were screen failures. A total of 550 subjects randomized, of which 471 received study treatment and 433 and 73 completed the main study for treatment and placebo, respectively. Recruitment July 2017-July 2018.</recruitment_details>
      <pre_assignment_details>This study included healthy volunteers (2 - 17 years) who were not previously immunized against cholera. A total of 574 subjects were screened, of which 24 were screen failures. A total of 550 subjects randomized, of which 471 received study treatment and 506 and 62 completed the main and sub studies, respectively. Recruitment July 2017-July 2018.&#xD;
The historical control subjects are not included in the protocol enrollment number for PXVX-VC-200-006. They are solely a comparator population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Active, 12-17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 (Placebo, 12 - 17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 (Placebo, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
          <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3 (Placebo, 2 - 5 Yrs)</title>
          <description>Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="P7">
          <title>Historical Control: Adult Bridging Population</title>
          <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study (Day 1 - 181)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="150"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="2688"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="130"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="2687"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Exl 8 and randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Placebo Crossover (Day 181-365)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">Only placebo subjects who opted to receive Vaxchora were included in the crossover group.</participants>
                <participants group_id="P2" count="0">Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora.</participants>
                <participants group_id="P3" count="11">Only placebo subjects who opted to receive Vaxchora were included in the crossover group.</participants>
                <participants group_id="P4" count="0">Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora</participants>
                <participants group_id="P5" count="7">Only placebo subjects who opted to receive Vaxchora were included in the crossover group.</participants>
                <participants group_id="P6" count="0">Placebo subjects from Main study opted to cross over to the active group to receive Vaxchora</participants>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up (Day 365-730)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73">Cohort 1 subjects from the main study had to opt to be included in the Long-term follow-up study.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Cohort 2 subjects were not eligible for the Long-term follow-up study.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0">Cohort 3 subjects were not eligible for the Long-term follow-up study.</participants>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not want lab drawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 (Active, 12-17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 (Placebo, 12 - 17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 (Placebo, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
          <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3 (Placebo, 2 - 5 Yrs)</title>
          <description>Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="B7">
          <title>Historical Control: Adult Bridging Population</title>
          <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="158"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="150"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="2688"/>
            <count group_id="B8" value="3238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="150"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2688"/>
                    <measurement group_id="B8" value="2688"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.4" spread="1.7"/>
                    <measurement group_id="B2" value="14.3" spread="1.7"/>
                    <measurement group_id="B3" value="8.6" spread="1.8"/>
                    <measurement group_id="B4" value="8.7" spread="1.5"/>
                    <measurement group_id="B5" value="3.5" spread="1.1"/>
                    <measurement group_id="B6" value="3.6" spread="1.2"/>
                    <measurement group_id="B7" value="30.0" spread="7.8"/>
                    <measurement group_id="B8" value="9.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="1482"/>
                    <measurement group_id="B8" value="1746"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="1206"/>
                    <measurement group_id="B8" value="1492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="56"/>
                    <measurement group_id="B8" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="671"/>
                    <measurement group_id="B8" value="842"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="1855"/>
                    <measurement group_id="B8" value="2184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="150"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="2341"/>
                    <measurement group_id="B8" value="2891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="347"/>
                    <measurement group_id="B8" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
        <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Placebo, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12-17 Yrs) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
          <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="95.4" upper_limit="99.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to co-primary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval</non_inferiority_desc>
            <param_type>Proportion</param_type>
            <param_value>0.985</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 (6 to &lt;12 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
        <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (Placebo, 6-11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 (6 to &lt;12 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
          <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="92.5" upper_limit="99.4"/>
                    <measurement group_id="O2" value="4.2" lower_limit="0.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to coprimary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval.</non_inferiority_desc>
            <param_type>Proportion</param_type>
            <param_value>0.985</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 3 (2 to &lt;6 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
        <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 (Placebo, 2-5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 3 (2 to &lt;6 Years) Primary Endpoint - Seroconversion of Serum Vibriocidal Antibody Against V. Cholerae</title>
          <description>The proportion of subjects achieving seroconversion of serum vibriocidal antibody (SVA) against the classical Inaba biotype of V. cholerae at Day 11 following one dose of VAXCHORA, defined as a 4-fold or greater rise over baseline Day 1 SVA titer.</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="91.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This analysis was based on the lower confidence limit and did not entail a comparative group. The requirement was for the lower limit of the 98.3% CI be at least 70%. Multiplicity adjustment due to coprimary endpoints allotted alpha=0.017 to this endpoint resulting in a 98.3% confidence interval.</non_inferiority_desc>
            <param_type>Proportion</param_type>
            <param_value>0.985</param_value>
            <ci_percent>98.3</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 (12-17 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
        <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control: Adult Bridging Population</title>
            <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12-17 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
          <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="2687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="95.4" upper_limit="99.9"/>
                    <measurement group_id="O2" value="93.5" lower_limit="92.3" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.8</param_value>
            <ci_percent>96.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
            <estimate_desc>Newcombe method of determining the difference between two independent binomial distributions</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 (6-11 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
        <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 (Active, 6-11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control: Adult Bridging Population</title>
            <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 (6-11 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
          <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="2687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="92.5" upper_limit="99.4"/>
                    <measurement group_id="O2" value="93.5" lower_limit="92.3" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.3</param_value>
            <ci_percent>96.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 3 (2-5 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
        <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of18 and 45 years.</description>
        <time_frame>Day 11</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 (Active, 2-5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control: Adult Bridging Population</title>
            <description>This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 3 (2-5 Yrs) Primary Endpoint - Non-inferiority of Seroconversion Rate at Day 11 Relative to Adults Aged 18 - 45 Years</title>
          <description>The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the pediatric seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of18 and 45 years.</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="2687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="91.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="93.5" lower_limit="92.3" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was determined using the Newcombe method of determining the difference between two independent binomial distributions. Multiple comparison adjustment for co-primary endpoints allotted alpha=0.033 to this comparison. The lower limit of the 96.7% CI needed to be greater than -10 percentage points to prove non-inferiority.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.5</param_value>
            <ci_percent>96.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 29</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Placebo, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 29</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p&lt;0.0001).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 91</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 91 for all subjects</description>
        <time_frame>Day 91</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Placebo, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 91</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 91 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" lower_limit="79.2" upper_limit="90.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p&lt;0.0001).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 181</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 181 for all subjects</description>
        <time_frame>Day 181</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Placebo, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 181</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 181 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="66.0" upper_limit="79.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p&lt;0.0001).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 365</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 365 for all subjects</description>
        <time_frame>Day 365</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 365</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 365 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="57.0" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 547</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 547 for all subjects</description>
        <time_frame>Day 547</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 547</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 547 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="61.5" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 730</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 730 for all subjects</description>
        <time_frame>Day 730</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 (12 to &lt;18 Years) - Seroconversion of SVA - Day 730</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 730 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="52.1" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2 (6 to &lt;12 Years) - Seroconversion of SVA - Day 29</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (Placebo, 6-11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 (6 to &lt;12 Years) - Seroconversion of SVA - Day 29</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="89.9" upper_limit="97.5"/>
                    <measurement group_id="O2" value="4.3" lower_limit="0.8" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p&lt;0.0001).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 3 (2 to &lt;6 Years) - Seroconversion of SVA - Day 29</title>
        <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity Evaluable Population (IEP)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 (Placebo, 2-5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of placebo on Day 1, and had study visits on Day 11, 29, 91 and 181.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 3 (2 to &lt;6 Years) - Seroconversion of SVA - Day 29</title>
          <description>Seroconversion of SVA against the classical Inaba biotype of V. cholerae at Day 29 for all subjects</description>
          <population>Immunogenicity Evaluable Population (IEP)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="87.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Fisher's exact test was used to compare Vaxchora vaccine to placebo on the percent of subjects who seroconverted. For Vaxchora vs placebo within each cohort at each Day on study timepoint, the p-value was the same (p&lt;0.0001).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 1</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 1 for the subjects in the active treatment group and the placebo crossover group</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 91</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 91 for the subjects in the active treatment group and the placebo crossover group</description>
        <time_frame>Day 91</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 181</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 181 for the subjects in the active treatment group and the placebo crossover group</description>
        <time_frame>Day 181</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 365</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 365 for the subjects in the active treatment group who participate in the substudy.</description>
        <time_frame>Day 365</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 547</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 547 for the subjects in the active treatment group who participate in the substudy.</description>
        <time_frame>Day 547</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1 (12 to &lt;18 Years) Exploratory Endpoint - Anti-O1 Lipopolysaccharide Memory B Cell Concentration at Day 730</title>
        <description>Anti-O1 lipopolysaccharide (LPS) memory B cell concentration at Day 730 for the subjects in the active treatment group who participate in the substudy.</description>
        <time_frame>Day 730</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety - Solicited Adverse Events</title>
        <description>Evaluate the safety and tolerability of VAXCHORA by collecting solicited adverse events (abdominal pain, headache, lack of appetite, tiredness, diarrhea, nausea, vomiting and fever) by age cohort and overall through Day 8</description>
        <time_frame>Through Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety - Unsolicited Adverse Events</title>
        <description>Evaluate the safety and tolerability of VAXCHORA by collecting unsolicited adverse events by age cohort and overall through Day 29</description>
        <time_frame>Through Day 29</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety - Serious Adverse Events</title>
        <description>Evaluate the safety and tolerability of VAXCHORA by collecting serious adverse events by age cohort and overall through Day 181</description>
        <time_frame>Through Day 181</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acceptability</title>
        <description>Evaluate the acceptability of VAXCHORA using the percent of subjects in each age cohort able to complete the dosing according to protocol.</description>
        <time_frame>Day 1</time_frame>
        <population>The data presented is for the population that was randomized and received treatment. For Cohort 2, 2 Vaxchora subjects and 1 placebo subject were randomized, but not treated. For Cohort 3, 4 Vaxchora subjects were randomized, but not treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Active, 12-17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Placebo, 12 - 17 Yrs)</title>
            <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Placebo, 6 - 11 Yrs)</title>
            <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
            <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Placebo, 2 - 5 Yrs)</title>
            <description>Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability</title>
          <description>Evaluate the acceptability of VAXCHORA using the percent of subjects in each age cohort able to complete the dosing according to protocol.</description>
          <population>The data presented is for the population that was randomized and received treatment. For Cohort 2, 2 Vaxchora subjects and 1 placebo subject were randomized, but not treated. For Cohort 3, 4 Vaxchora subjects were randomized, but not treated.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="146"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="91.0"/>
                    <measurement group_id="O4" value="96.2"/>
                    <measurement group_id="O5" value="79.5"/>
                    <measurement group_id="O6" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected for 28 days post vaccination. Serious adverse events were followed until the end of the end of the subject's participation in the study (2 years for adolescents in the long term sub-study and 6 months for all others). Solicited adverse events were collected for daily for 8 consecutive days following vaccination (Days 1-8). Events that continued past Day 8 were recorded as unsolicited adverse events.</time_frame>
      <desc>The Historical Control population is not included in this section as comparisons between the pediatric and adult populations were not specified to be conducted in the protocol.&#xD;
The data below is not for randomized subjects, but for those included in the safety population.&#xD;
For cohort 1, 2 subjects received Vaxchora instead of placebo; the subject count is 165 Vaxchora : 24 placebo.&#xD;
For cohort 2, 1 subject received Vaxchora instead of placebo; the subject count is 157 Vaxchora : 25 placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (Active, 12-17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 (Placebo, 12 - 17 Yrs)</title>
          <description>Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 (Active, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 (Placebo, 6 - 11 Yrs)</title>
          <description>Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3 (Active, 2 - 5 Yrs)</title>
          <description>Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
VAXCHORA (Cholera Vaccine, Live, Oral): VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3 (Placebo, 2 - 5 Yrs)</title>
          <description>Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.&#xD;
Placebo: Placebo control for this study is normal (0.9%) saline.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="146"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="130" subjects_affected="62" subjects_at_risk="165"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="83" subjects_affected="43" subjects_at_risk="157"/>
                <counts group_id="E4" events="15" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" events="53" subjects_affected="25" subjects_at_risk="146"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="69" subjects_affected="37" subjects_at_risk="165"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" events="37" subjects_affected="22" subjects_at_risk="157"/>
                <counts group_id="E4" events="11" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rectal Tenesmus</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="170" subjects_affected="67" subjects_at_risk="165"/>
                <counts group_id="E2" events="30" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" events="123" subjects_affected="55" subjects_at_risk="157"/>
                <counts group_id="E4" events="17" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E5" events="108" subjects_affected="45" subjects_at_risk="146"/>
                <counts group_id="E6" events="13" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vessel Puncture site pain</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of Appetite</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="112" subjects_affected="48" subjects_at_risk="165"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="47" subjects_affected="24" subjects_at_risk="157"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E5" events="63" subjects_affected="28" subjects_at_risk="146"/>
                <counts group_id="E6" events="8" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lack of Appetite</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited Day 1 - 8</description>
                <counts group_id="E1" events="191" subjects_affected="74" subjects_at_risk="165"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E3" events="77" subjects_affected="41" subjects_at_risk="157"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" events="18" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Unsolicited Day 29</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Cassie, Scientist, Clinical Research</name_or_title>
      <organization>Emergent BioSolutions Canada Inc.</organization>
      <phone>204-275-4589</phone>
      <email>dcassie@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

